Last reviewed · How we verify
Bacteriophage Treatment
Bacteriophages selectively infect and kill bacteria
Bacteriophages selectively infect and kill bacteria Used for Bacterial infections.
At a glance
| Generic name | Bacteriophage Treatment |
|---|---|
| Sponsor | NYU Langone Health |
| Drug class | Bacteriophage |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Bacteriophages are viruses that target bacterial cells, causing them to lyse and die. This mechanism is particularly useful in treating bacterial infections that are resistant to traditional antibiotics.
Approved indications
- Bacterial infections
Common side effects
Key clinical trials
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia (PHASE1, PHASE2)
- A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) (PHASE2)
- Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus (PHASE1, PHASE2)
- Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis (PHASE3)
- Bacteriophage Therapy for Staphylococcus Lugdunensis Prosthetic Joint Infection (PHASE1, PHASE2)
- Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection (PHASE1)
- Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |